LEXINGTON, Mass. -- (BUSINESS WIRE) -- Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the company will present data on the latest developments related to its CertNDxTM Bladder Cancer Assays at two upcoming scientific conferences, the Molecular Med Tri-Con 2013 and ASCO’s 2013 Genitourinary Cancers Symposium.
Anthony P. Shuber, chief technology officer, will present at Molecular Med Tri-Con 2013, which takes place on Feb. 11-15 at the Moscone North Convention Center in San Francisco. In a luncheon presentation entitled “Maximizing Clinical Utility of Non-Invasive Biomarkers “ on Wednesday, Feb. 13 at 1:10 p.m. PST, Mr. Shuber will provide an update on the development of the company’s novel approaches, technologies and CertNDx products for cancer molecular diagnostics.
John M. Millholland, Ph.D., senior scientist, will present at the 2013 Genitourinary Cancers Symposium, which takes place on Feb. 14-16 at Rosen Shingle Creek in Orlando, FL. In a poster presentation on Friday, Feb. 15, Dr. Millholland will present “Combining next-generation sequencing of TP53 and FGFR3 for the detection of bladder cancer-related mutations”. The company has developed a new next-generation sequencing-based assay to run the analysis for both p53 and FGFR3, which is expected to be available in early 2013.
“We continue to strengthen our biomarker portfolio and utilize the latest technologies such as next-generation sequencing to improve the accuracy and clinical performance of our assays,” said Pierre Cassigneul, chief executive officer at Predictive Biosciences. “We are pleased to have the opportunity to present our most recent data at these important scientific conferences.”
The CertNDx Bladder Cancer Assays are a suite of molecular diagnostic tests that can assist physicians in the diagnosis and treatment of bladder cancer. CertNDx testing is available in a voided, urine-based test for Hematuria Assessment and Recurrence Monitoring as well as a tissue-based prognostic test for Molecular Grading. To learn more about CertNDx testing please visit: www.predictivebiosci.com.
About Predictive Biosciences
Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. Predictive Biosciences’ new approach to molecular testing analyzes multiple biomarkers (DNA and protein) together in a single test to determine disease state. The company’s CertNDx™ tests enable physicians to accurately detect cancer. Headquartered in Lexington, Mass., the company is backed by leading investors including Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, New Enterprises Associates, Inc. (NEA) and ProQuest Investments. For additional information, please visit www.predictivebiosci.com.